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Abstract
Background:  Genetic polymorphisms of DNA repair enzymes may lead to genetic instability and
colorectal cancer carcinogenesis. Our objective was to measure the interactions between polymorphisms
of repair genes and tobacco smoking in colorectal cancer.
Methods: The case-control study involved sixty-eight colorectal cancer patients and 121 non-cancer
controls divided into non-smokers and smokers according to pack-years of smoking. The genetic
polymorphisms of DNA repair enzymes,OGG1 Ser326Cys,  MUTYH Gln324His,  APEX1 Asp148Glu and
XRCC1 Arg399Gln, were examined using PCR-RFLP.
Results: The MUTYH Gln324His showed strong significant associations with a risk of colorectal cancer
(crude odds ratio [OR] 3.30, 95% confidence interval [95%CI] 1.44–7.60, p = 0.005; adjusted OR3.53,
95%CI 1.44–8.70, p = 0.006). The ORs for the APEX1 Asp148Glu were statistically significant (crude OR
2.69, 95%CI 1.45–4.99, p = 0.002; adjusted OR 2.33, 95%CI 1.21–4.48, p = 0.011). The ORs for the MUTYH
Gln324His and the APEX1 Asp148Glu were statistically significant for colon cancer (adjusted OR 3.95,
95%CI 1.28–12.20, p = 0.017 for MUTYH Gln324His ; adjusted OR 3.04, 95%CI 1.38–6.71, p = 0.006 for
APEX1 Asp148Glu). The joint effect of tobacco exposure and the MUTYH Gln324His showed a significant
association with colorectal cancer risk in non-smokers (adjusted OR 4.08, 95%CI 1.22–13.58, p = 0.022)
and the APEX1 Asp148Glu was significantly increased in smokers (adjusted OR 5.02, 95%CI 1.80–13.99, p
= 0.002). However, the distributions of OGG1 Ser326Cys and XRCC1 Arg399Gln were not associated with
a colorectal cancer risk.
Conclusion: Our findings suggest that the MUTYH Gln324His and the APEX1 Asp148Glu constitutes an
increased risk of colorectal cancer, especially colon cancer. The MUTYH Gln324His is strongly associated
with colorectal cancer susceptibility in never smoking history, whereas the APEX1 Asp148Glu genotype
constitutes an increased risk of colorectal cancer when accompanied by smoking exposure.
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Introduction
Colorectal cancer is a major cause of death and is influ-
enced by genetic characteristics and environmental fac-
tors. Humans are exposed daily to a large variety of toxic
and carcinogenic compounds due to habits such as
tobacco smoking. Tobacco smoking produces major
classes of carcinogenic compounds: polycyclic aromatic
hydrocarbons (PAHs), aromatic amines, and heterocyclic
amines (HCA). Several of these compounds can produce
bulky DNA adducts [1]. The colorectal mucosa is exposed
to these compounds through either the alimentary tract or
the circulatory system. DNA adducts were detected in the
colonic mucosa of smokers than in nonsmokers [2]. A
previous study found that heavy smokers have a 2–3-fold
elevated risk of colorectal adenoma [3]. Our previous data
showed that genetic polymorphisms of NAT2  and
CYP1A2 in metabolic processes contributed to colorectal
cancer risk depending on smoking status in Japanese pop-
ulation [4]. Therefore, tobacco smoking might be a poten-
tial risk factor for colorectal cancer.
DNA repair genes are increasingly being studied for cancer
risk because of their critical role in maintaining genome
integrity. The base excision repair (BER) pathway, one of
four major DNA repair pathways, has a principal role in
the repair of mutations caused by oxidized or reduced
bases [5]. Therefore, polymorphisms of DNA repair genes
may increase the risk of colorectal cancer. In addition,
smoking-induced oxidative DNA base modifications and
single-strand breaks are repaired by the BER pathway. In
the current study, we focused on genes encoding four key
proteins in the BER pathway: OGG1 (8-oxoguanine DNA
glycosylase), MUTYH/MYH (Mut Y homolog), APEX1/
APE1 (Apurinic/apyrimidinic endonuclease-1), and
XRCC1 (X-ray cross-complementing group 1).OGG1 is a
DNA glycosylase that removes 8-oxo-7, 8-dihydro-2'-
deoxyguanosine (8-oxo-G), which is the most stable form
of a highly mutagenic oxidative DNA adduct that pairs
with cytosine [6]. MUTYH is another DNA glycosylase
that removes adenine paired with 8-oxo-G or 1, 2-dihy-
dro-2-oxoadenine (2-OH-A) paired with guanine [7]. The
2-OH-A level is increased by exposure to reactive oxygen
species [8]. APEX1 removes abasic sites formed in DNA
cleavage by OGG1 and MUTYH and recruits DNA
polymerase β and DNA ligase III [9]. X-ray cross-comple-
menting group 1 (XRCC1) is a multidomain protein that
interacts with poly-ADP-ribose polymerase, DNA ligase III
and DNA polymerase β, and repairs DNA single-strand
breaks by generating a single nucleotide repair patch
(short-patch BER)[10].
We conducted a hospital-based case-control study to elu-
cidate the DNA repair gene polymorphisms, OGG1
Ser326Cys  (rs1052133),  MUTYH Gln324His
(rs3219489),APEX1 Asp148Glu (rs1130409) and XRCC1
Arg399Gln  (rs25487).  OGG1 Ser326Cys,  APEX1
Asp148Glu and XRCC1 Arg399Gln have also been linked
to a risk of colorectal cancer [11-13]. Germ-line variants,
Tyr165Cys and Gly382Asp, of the MUTYH gene have been
associated with colorectal adenomas in Caucasians, not in
Asians [14-16]. Recent studies reported that MUTYH
Gln324His mutation was the most frequent mutation in
Japanese patients with adenomatous popyposis, and the
gene polymorphisms was associated with the risk of prox-
imal colon cancer in the Japanese population [17,18]. To
our knowledge, few previous studies have examined the
effect of these polymorphisms on the association between
smoking and colorectal cancer [19,20]. These polymor-
phisms were analyzed to evaluate genetic susceptibility to
colorectal cancer and the possible modification effect on
the relationship between smoking and colorectal cancer
risk.
Materials and methods
Subjects
A total of 68 colorectal cancer patients (40 with colon can-
cer, 23 with rectal cancer, and 5 with unknown) were
recruited into the study between October 2003 and March
2005 at the Kobe Medical Center and Kobe Rosai Hospital
in Kobe, Japan. Patients were eligible if they underwent
major colon or rectal surgery for a diagnosis of primary
colon or rectal cancer. A total of 121 controls with no cur-
rent or previous diagnosis of cancer were recruited
between November 2002 and March 2003, as reported in
our previous study [4]. The study design was approved by
the Ethics Review Committee on Genetic and Genomic
Research, Kobe University Graduate School of Medicine.
Informed consent was obtained and detailed data on
smoking were collected in a personal interview. The
amount of smoke exposure was calculated in pack-years:
the product of the number of years an individual had
smoked and the average number of cigarettes smoked per
day, converted into a standard pack of 20 cigarettes. Sam-
ples were coded after blood and data collection.
Genotyping
Genomic DNA used in the study was isolated for a previ-
ous study [4]. For MUTYH Gln324His, PCR was performed
in a 25-μL reaction mixture containing 50 ng DNA, 250
mmol/l of each primer, 250 μmol/l of dNTPs, 1× PCR
buffer, and 0.75 U of Ex Taq DNA polymerase (Takara,
Shiga, Japan) using a programmable thermocycler PC-701
(Astec K.K, Fukuoka, Japan). The primer sequences were
5'-TGC CGA TTC CCT CCA TTC TCT CTT G-3' and 5'-TCT
TGG CTT GAG TAG GGT TCG GG-3'. PCR conditions
were 3 min at 94°C; 38 cycles of 1 min at 94°C, 1 min at
64°C, and 1 min at 72°C; followed by final extension for
10 min at 72°C. After amplification, the PCR products
were digested with HpyCH4 III (New England Biolabs,
Beverly, MA) for 4 h at 37°C in a final volume of 23 μl.Journal of Experimental & Clinical Cancer Research 2008, 27:49 http://www.jeccr.com/content/27/1/49
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Digested fragments were separated by electrophoresis on
12% polyacrylamide gel and visualized by ethidium bro-
mide staining using a 20-bp DNA Ladder (Takara, Shiga,
Japan) as a size marker. All experiments included positive
and negative controls for each polymorphism. In PCR-
RFLP genotyping of MUTYH, complete digestion of PCR
products produced 292-bp fragments for the Gln allele,
and 239-bp and 53-bp fragments for the His allele (the 53-
bp fragment was too small to resolve accurately)(Figure
1). The genotypes of OGG1 Ser326Cys [21],  APEX1
Asp148Glu [22], and XRCC1 Arg399Gln [23] were deter-
mined by PCR-RFLP analysis.
Statistical analysis
Differences in demographic variables, smoking and
grouped genotypic frequencies between the patients and
controls were evaluated using a Chi-square test. All
reported P-values are two-sided with p < 0.05 considered
to be significant. Hardy-Weinberg equilibrium was tested
using a Chi-square test to compare the observed genotype
frequencies with the expected frequencies among the con-
trol subjects. The association between variant genotypes
and risk of colorectal cancer was estimated by computing
the odds ratios (OR) and the 95% confidence interval
(95%CI) from unconditional logistic regression analysis,
adjusted for age, gender, and smoking habit. Statistical
analysis was performed with SPSS software (version 14.0
for Windows; SPSS Japan Inc., Tokyo, Japan). The subjects
were divided into two groups according to pack-years of
smoking: non-smokers (pack-years = 0), and smokers
(pack-years > 0). The OR for each variant genotype was
calculated for each subgroup.
Results
The study included 68 patients and 121 controls (Table
1). The distribution of males (patients, 54.4%; controls,
61.2%) and females (patients, 38.2%; controls, 38.8%)
did not differ significantly between the two groups (p =
0.872), and there was also no difference in the average age
(± SD) of the patients (67.3 ± 10.9 years old) and controls
(67.4 ± 6.7 years old) (p = 0.923). Non-smokers com-
prised 52.9% of patients and 45.5% of controls and smok-
ers comprised 38.2% of patients and 49.6% of controls.
There was no difference in smoking status between
patients and controls (p = 0.253). Subsites were divided
into 40 colon (58.8%) and 23 rectum (33.8%), and 5
unknown (7.4%).
Genotyping and allele frequencies of OGG1
Ser326Cys,MUTYH Gln324His,APEX1 Asp148Glu, and
XRCC1 Arg399Gln adjusted for gender, age and smoking
habit are shown in Table 2. The allele frequencies of the
four gene polymorphisms in controls were consistent
with the Hardy-Weinberg equilibrium. The ORs for the
OGG1 Ser/Cys and Cys/Cys genotypes compared with the
Ser/Ser genotype were not statistically significant (crude
odds ratio [OR] 1.43, 95% confidence interval [95%CI]
0.73–2.78, p = 0.297; adjusted OR 1.43, 95%CI 0.69–
2.95, p = 0.332). The ORs for the MUTYH Gln/His and His/
His genotypes were shown to be statistically associated
with the Gln/Gln genotype (crude OR 3.30, 95%CI 1.44–
7.60, p = 0.005; adjusted OR3.53, 95%CI 1.44–8.70, p =
0.006). The ORs for the APEX1 Asp/Glu and Glu/Glu geno-
types compared with Asp/Asp genotype were significantly
increased (crude OR 2.69, 95%CI 1.45–4.99, p = 0.002;
adjusted OR 2.33, 95%CI 1.21–4.48, p = 0.011). The ORs
for the XRCC1 Arg/Gln and Gln/Gln genotypes compared
with the Arg/Arg genotype were not statistically significant
(crude OR 0.65, 95%CI 0.36–1.19, p = 0.164; adjusted
OR 0.60, 95%CI 0.31–1.15, p = 0.125). These results indi-
cate that the MUTYH Gln324His and the APEX1
Asp148Glu  carry a significant risk for carcinogenesis of
colorectal cancer.
The distributions of the four polymorphisms were com-
pared among cases of colon and rectal cancer, and the OR
adjusted for gender, age and smoking habit is shown in
Table 3. The adjusted ORs for the OGG1 Ser/Cys and Cys/
Cys genotypes compared with the Ser/Ser genotype were
not statistically significant (OR 1.28, 95%CI 0.55–2.99, p
= 0.567 for colon cancer; OR 1.66, 95%CI 0.56–4.87, p =
0.359 for rectal cancer). The adjusted ORs for the MUTYH
Gln/His and His/His genotypes were significant compared
with the Gln/Gln genotype for colon cancer, but not for
rectal cancer (OR 3.95, 95%CI 1.28–12.20, p = 0.017 for
colon cancer; OR 3.06, 95%CI 0.84–11.11, p = 0.089 for
rectal cancer). The adjusted ORs for the APEX1 Asp/Glu
and Glu/Glu genotypes compared with Asp/Asp genotype
Representative result for the MUTYH Gln324His polymor- phisms by PCR-RFLP methods Figure 1
Representative result for the MUTYH Gln324His poly-
morphisms by PCR-RFLP methods. Lane M, markers; 
lane 1, His/His; lane 2, Gln/His; lane 3, Gln/Gln.
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were statistically significant for colon cancer, but not for
rectal cancer (OR 3.04, 95%CI 1.38–6.71, p = 0.006 for
colon cancer; OR 1.61, 95%CI 0.64–4.09, p = 0.315 for
rectal cancer). The adjusted ORs for the XRCC1 Arg/Gln
and Gln/Gln genotypes compared with the Arg/Arg geno-
type were not statistically significant (OR 0.60, 95%CI
0.28–1.30, p = 0.194 for colon cancer; OR 0.62, 95%CI
0.24–1.58, p = 0.315 for rectal cancer).Therefore, the can-
cer subsite-specific study indicated that the MUTYH
Gln324His and the APEX1 Asp148Glu have a colon cancer-
specific risk.
Table 1: Characteristics of colorectal cancer case and control subjects
Item Patients Controls P-value
n% n %
Number 68 121
Gender
m a l e s 3 7 5 4 . 47 46 1 . 2 0 . 8 7 2 a
f e m a l e s 2 6 3 8 . 24 73 8 . 8
u n k n o w n 5 7 . 400 . 0
Age
~ 6 4 2 1 3 0 . 95 04 1 . 3
6 5 ~ 6 9 1 3 1 9 . 12 92 4 . 0
7 0 ~ 7 4 1 3 1 9 . 12 01 6 . 5
7 5 ~ 1 6 2 3 . 52 21 8 . 2
u n k n o w n 5 7 . 400 . 0
Mean ± S.D. 67.3 ± 10.9 67.4 ± 6.7 0.923b
Smoking status (Pack-years)
non-smokers (Pack-years = 0) 36 52.9 55 45.5 0.253a
smokers (Pack-years > 0) 26 38.2 60 49.6
u n k n o w n 6 8 . 865 . 0
Subsites
colon 40 58.8
rectum 23 33.8
unknown 5 7.4
a: X2 analysis
b: Student's T-test
Table 2: Genotype distribution in colorectal cancer and Allele frequency
Allele frequency
Genotype patients (n = 68) controls (n = 121) crude adjusted patients controls
n % n % OR (95%CI) p OR (95%CI)a p %%
OGG1
Ser/Ser 17 25.0 39 32.2 1.00 1.00 Ser 52.9 54.6
Ser/Cys,Cys/Cys 51 75.0 82 67.8 1.43 (0.73–2.78) 0.297 1.43 (0.69–2.95) 0.332 Cys 47.1 45.5
MUTYH
Gln/Gln 8 11.8 37 30.6 1.00 1.00 Gln 39.0 59.1
Gln/His,His/His 60 88.2 84 69.4 3.30 (1.44–7.60) 0.005 3.53 (1.44–8.70) 0.006 His 61.0 40.9
APEX1
Asp/Asp 23 33.8 70 57.9 1.00 1.00 Asp 64.0 74.8
Asp/Glu,Glu/Glu 45 66.2 51 42.1 2.69 (1.45–4.99) 0.002 2.33 (1.21–4.48) 0.011 Glu 36.0 25.2
XRCC1
Arg/Arg 42 61.8 62 51.2 1.00 1.00 Arg 78.7 71.1
Arg/Gln,Gln/Gln 26 38.2 59 48.8 0.65 (0.36–1.19) 0.164 0.60 (0.31–1.15) 0.125 Gln 21.3 28.9
a: OR adjusted for gender, age, smoking habitJ
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Table 3: Genotype distribution in relation to subsites in colorectal cancer
Genotype Colon cancer Rectal cancer
patients 
(n = 40)
controls 
(n = 121)
crude adjusted patients 
(n = 23)
controls 
(n = 121)
crude adjusted
n % n % OR 
(95%CI)
p OR (95%CI)a P n % n % OR 
(95%CI)
p OR (95%CI)a p
OGG1
Ser/Ser 10 25.0 39 32.2 1.00 1.00 5 21.7 39 32.2 1.00 1.00
Ser/Cys,Cys/Cys 30 75.0 82 67.8 1.43 
(0.63–3.21)
0.390 1.28 
(0.55–2.99)
0.567 18 78.3 82 67.8 1.71 
(0.59–4.95)
0.321 1.66 
(0.56–4.87)
0.359
MUTYH
Gln/Gln 4 10.0 37 30.6 1.00 1.00 3 13.0 37 30.6 1.00 1.00
Gln/His,His/His 36 90.0 84 69.4 3.96 
(1.32–11.95)
0.014 3.95 
(1.28–12.20)
0.017 20 87.0 84 69.4 2.94 
(0.82–10.49)
0.097 3.06 
(0.84–11.11)
0.089
APEX1
Asp/Asp 12 30.0 70 57.9 1.00 1.00 11 47.8 70 579 1.00 1.00
Asp/Glu,Glu/Glu 28 70.0 51 42.1 3.20 
(1.49–6.89)
0.003 3.04 
(1.38–6.71)
0.006 12 52.2 51 42.1 1.50 
(0.61–3.66)
0.376 1.61 
(0.64–4.09)
0.315
XRCC1
Arg/Arg 25 62.5 62 51.2 1.00 1.00 14 60.9 62 51.2 1.00 1.00
Arg/Gln,Gln/Gln 15 37.5 59 48.8 0.63 
(0.30–1.31)
0.217 0.60 
(0.28–1.30)
0194 9 39.1 59 48.8 0.68 
(0.27–1.68)
0.398 0.62 
(0.24–1.58)
0.315
a: OR adjusted for gender, age, smoking habitJ
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Table 4: Genotype distribution in relation to smoking status in colorectal cancer
Genotype non-smokers (Pack-years = 0) smokers (Pack-years > 0)
patients 
(n = 36)
controls 
(n = 55)
crude adjusted Patients 
(n = 26)
controls 
(n = 60)
crude adjusted
n%n% O R  
(95%CI)
p OR (95%CI)a p N % n % OR 
(95%CI)
p OR (95%CI)a p
OGG1
Ser/Ser 8 22.2 14 25.5 1.00 1.00 7 26.9 23 38.3 1.00 1.00
Ser/Cys,Cys/Cys 28 77.8 41 74.5 1.20 
(0.44–3.23)
0.725 1.14 
(0.41–3.13)
0.807 19 73.1 37 61.7 1.69 
(0.61–4.64)
0.310 1.68 
(0.60–4.67)
0.321
MUTYH
Gln/Gln 4 11.1 18 32.7 1.00 1.00 3 11.5 17 28.3 1.00 1.00
Gln/His,His/His 32 88.9 37 67.3 3.89 
(1.19–12.69)
0.024 4.08 
(1.22–13.58)
0.022 23 88.5 43 71.7 3.03 
(0.80–11.43)
0.102 2.95 
(0.77–11.25)
0.113
APEX1
Asp/Asp 15 41.7 29 52.7 1.00 1.00 8 30.8 41 68.3 1.00 1.00
Asp/Glu,Glu/Glu 21 58.3 26 47.3 1.56 
(0.67–3.65)
0.303 1.56 
(0.66–3.68)
0.311 18 69.2 19 31.7 4.86 
(1.80–13.13)
0.002 5.02 
(1.80–13.99)
0.002
XRCC1
Arg/Arg 20 55.6 29 52.7 1.00 1.00 18 69.2 30 50.0 1.00 1.00
Arg/Gln,Gln/Gln 16 44.4 26 47.3 0.89 
(0.38–2.08)
0.791 0.86 
(0.37–2.03)
0.732 8 30.8 30 50.0 0.44 
(0.17–1.18)
0.103 0.43 
(0.16–1.16)
0.097
a: OR adjusted for gender, ageJournal of Experimental & Clinical Cancer Research 2008, 27:49 http://www.jeccr.com/content/27/1/49
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The ORs for the combined effect of tobacco exposure
(pack-years) and the four polymorphisms, adjusted for
gender and age, are shown in Table 4. The adjusted ORs
for the OGG1 Ser/Cys and Cys/Cys genotypes compared
with the Ser/Ser genotype showed no statistically signifi-
cant risk in non-smokers and smokers (OR 1.14, 95%CI
0.41–3.13, p = 0.807 in non-smokers; OR 1.68, 95%CI
0.60–4.67, p = 0.321 in smokers). The adjusted ORs for
the  MUTYH Gln/His and  His/His  genotypes compared
with the Gln/Gln genotype showed a significant associa-
tion with colorectal cancer risk in non-smokers, but not in
smokers (OR 4.08, 95%CI 1.22–13.58, p = 0.022 in non-
smokers; OR 2.95, 95%CI 0.77–11.25, p = 0.113 for
smokers). These results show that the MUTYH Gln/His
and His/His genotypes are associated with colorectal can-
cer susceptibility with never smoking history. The
adjusted ORs for the APEX1 Asp/Glu and Glu/Glu geno-
types compared with the Asp/Asp genotype in smokers was
significantly increased (OR 5.02, 95%CI 1.80–13.99, p =
0.002), whereas that in non-smokers did not show a sig-
nificant (OR 1.56, 95%CI 0.66–3.68, p = 0.311). Smokers
with the APEX1 Asp/Glu and Glu/Glu genotypes showed an
increased risk of colorectal cancer. The adjusted ORs for
the XRCC1 Arg/Gln and Gln/Gln genotypes compared with
the Arg/Arg genotype were not statistically significant (OR
0.86, 95%CI 0.37–2.03, p = 0.732 in non-smokers; OR
0.43, 95%CI 0.16–1.16, p = 0.097 in smokers). These
results indicate that the MUTYH Gln324His and the APEX
Asp148Glu have statistically a significant risk of colorectal
cancer according to smoking status.
Discussion
The association between the risk of colorectal cancer and
polymorphisms of four DNA repair genes in the BER path-
way was investigated in a small case-control study. No sig-
nificant relationship was apparent between OGG1
Ser326Cys  and colorectal cancer risk. Previous reports
have suggested that OGG1 Ser326Cys is associated with
colorectal cancer in Caucasians [11,24], but not among
Koreans [25]. Our findings in a Japanese population are
consistent with the results from the Korean population
study.
Interestingly, we found that the MUTYH Gln324His geno-
type has a strong significant association with colorectal
cancer risk, especially colon cancer. Tao et al. [18] reported
MUTYH Gln324His in Japanese was statistically signifi-
cantly associated with increased risk of proximal colon,
but not distal colon or rectal cancer. Therefore, their
results are consistent with our study. Moreover, a recent
study found that the activity of MUTYH Gln324His is 34%
less active than that of wild type [26]. 8-oxo-G is generated
by direct oxidation of DNA by a hydroxyl radical, whereas
2-OH-A is exclusively generated by oxidation of dATP in
the nucleotide pool [6,7]. The 2-OH-A level is increased in
human cancerous tissues compared to normal tissues
[27]. Thus, for colorectal cancer, it is also possible that the
enzyme of MUTYH Gln324His may have partially
impaired in repair of 2-OH-A opposite guanine, com-
pared to repair of adenine opposite 8-oxo-G, because of
the difference in the origin of each oxidized base. We also
found that MUTYH Gln324His was statistically associated
with increased risk in never smokers. These results suggest
that the MUTYH 324His variation may be associated with
a risk of colorectal cancer due to an increased mutation
frequency, containing environmental factors except
smoking.
We indicated that the APEX1 Asp148Glu genotype has a
specifically association with colon cancer risk. A previous
study reported that this genotype was especially an
increased risk of colon cancer risk [28]. We also found a
statistically significant association between the APEX1
Asp148Glu genotype and colorectal cancer risk in combi-
nation with smoking exposure. Ito et al. [29] reported that
the gene-environment interaction between current smok-
ing and APEX1 148 Glu/Glu genotype was statistically sig-
nificant for lung cancer risk. However, a previous study
didn't found about the effect of smoking habit on associ-
ation between the APEX1 Asp148Glu genotype and color-
ectal cancer risk [28]. This polymorphism is located
within the endonuclease domain of the protein [30], but
it does not reduce endonuclease activity [31]. The 148 Glu
allele has also been associated with increased mitotic
delay after exposure to ionizing radiation [22]. Our results
indicate that the APEX1 variation may play an important
role in colorectal cancer risk, containing a reduced ability
to communicate with the other BER proteins. In contrast,
for XRCC1 Arg399Gln variants, we found no relationship
with colorectal cancer. The XRCC1 399Gln allele has been
linked with a reduced risk of colorectal adenomas [12,13],
and XRCC1 has also been associated with improved
progress in patients who underwent chemotherapy, but
not in those who received surgery alone [11]. The smok-
ing has an effect on colon adenoma risks among carriers
of XRCC1 codon 399 Arg alleles [19,20]. However, we
were unable to detect these relationships in our cases.
Our data may be biased by the relatively small number as
a hospital-based case-control study, because we have sev-
eral limitations. Therefore, we would require further veri-
fication as predictive biomarkers in a larger study
population and need to clarify the gene-environment
interaction between smoking and these genotypes.
In conclusion, MUTYH Gln324His and APEX1 Asp148Glu
polymorphisms are important risk factors for colorectal
cancer, especially colon cancer, in the Japanese popula-
tion. In particular, the MUTYH Gln324His genotype is
associated with colorectal cancer susceptibility in neverJournal of Experimental & Clinical Cancer Research 2008, 27:49 http://www.jeccr.com/content/27/1/49
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smoking history, whereas the APEX1 Asp148Glu genotype
constitutes an increased risk of colorectal cancer in combi-
nation with smoking exposure. MUTYH Gln324His and
APEX1 Asp148Glu polymorphisms may be useful markers
of genetic susceptibility to colorectal cancer.
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